Destiny Pharma plc, of Brighton, U.K., selected the Surrey, U.K.-based contract research organization Medpharm Ltd. as its partner to develop new topical formulations of the company's XF platform compounds, potential new treatments for dermal and ocular infections. Destiny said one product of the platform, XF-73 nasal gel, for the prevention of post-surgical infections, will begin phase IIb testing in 2019.